Circulating DNA tumor fraction as a biomarker for advanced breast cancer
Liquid biopsy has emerged as an important clinical tool for managing a range of tumor types, including advanced breast cancers. Early work in metastatic breast cancer (MBC) demonstrated that circulating tumor DNA (ctDNA) could be reliably detected in patient peripheral blood samples. These discoveri...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2025-11-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1655415/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|